A study published Wednesday (May 18) in the journal Emerging Microbes & Infections found that participants who received follow-up medical care standard There were 60 patients who received VV116 and 76 were not given the drug.
.
The researchers found that the group of patients who received VV116 within five days following their first positive test result. The mean duration of elimination of the virus was 8.56 days, while the control group had an average of 11.13 days of elimination of the virus. Nine cases of mild adverse reactions were reported in the VV116 treatment group. Of these, 7 cases showed slightly abnormal liver function. Yet all were resolved without outside intervention.
.
YaVV116 is an anti-COVID-19 drug. Safe and effective diet by showing good potential in treating viral infections Early Omicron Species
.
The above drugs have been used in trials in patients with COVID-19. Moderate and severe symptoms worldwide The latter has been proven to be safe and well tolerated by side effects. (well-tolerated) in testing with healthy people
.
The developers of the drug come from several institutions under the Chinese Academy of Sciences (CAS), including Shanghai Junshi Biosciences Co., Ltd. and Wigonvita Life Sciences Co., Ltd. ( Vigonvita Life Sciences) in Suzhou City
.
source Xinhua news agency
